Cambridge Nutritional Science (CNSL)

Sector:

Health Care

Index:

FTSE AIM All-Share

4.10p
   
  • Change Today:
    -0.050p
  • 52 Week High: 4.35
  • 52 Week Low: 1.73
  • Currency: UK Pounds
  • Shares Issued: 237.95m
  • Volume: 26,037
  • Market Cap: £9.76m

Omega Diagnostics progresses Covid-19 test with EU, US regulators

By Josh White

Date: Tuesday 08 Jun 2021

LONDON (ShareCast) - (Sharecast News) - Medical diagnostics company Omega updated the market on regulatory approvals for the 'Visitect' Covid-19 antigen test on Tuesday, confirming that it has started engaging with its European notified body, seeking CE-marking of the test.
The AIM-traded firm described Visitect as a "rapid, point-of-care" diagnostic test for the detection of active Covid-19 infections, used as a self-test.

It said it was currently agreeing the protocols required for utilisation studies, and would issue updates as that process progressed.

The test was already CE-marked for professional use, with Omega targeting approval by the end of July to allow the test to be sold in Europe for home use as well.

As the global market for antigen testing developed, the company said it believed self-test approval would be a "key product differentiator", as had already been seen in the UK.

Omega also announced that its technology partner Mologic had successfully completed the necessary performance studies required for regulatory approval in the United States, and was now in the final stages of preparing a submission to the US Food and Drug Administration (FDA) requesting emergency use authorisation (EUA) for its rapid point-of-care Covid-19 antigen test, under both the Omega's Visitect brand and the 'Global Access Diagnostics' brand.

"I am pleased with the progress we are making to gain regulatory approval, both for our VISITECT self-test product and for US professional use," said chief executive officer Colin King.

"Both routes offer potentially significant opportunities as we believe we have a high quality product with global appeal."

At 0909 BST, shares in Omega Diagnostics were down 0.41% at 60.25p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CNSL Market Data

Currency UK Pounds
Share Price 4.10p
Change Today -0.050p
% Change -1.20 %
52 Week High 4.35
52 Week Low 1.73
Volume 26,037
Shares Issued 237.95m
Market Cap £9.76m

CNSL Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
88.39% above the market average88.39% above the market average88.39% above the market average88.39% above the market average88.39% above the market average
83.78% above the sector average83.78% above the sector average83.78% above the sector average83.78% above the sector average83.78% above the sector average
Income Not Available
Growth Not Available

CNSL Dividends

No dividends found

Trades for 23-Jul-2024

Time Volume / Share Price
08:13 1,332 @ 4.06p
08:04 20,000 @ 4.25p
08:01 4,705 @ 4.25p

Top of Page